Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ligand (LGND) Signs Licensing Deal with xCella Biosciences
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
Achaogen's Plazomicin Gets Breakthrough Therapy Designation
by Zacks Equity Research
Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.
Catalyst Pharmaceuticals Focuses on Development of Firdapse
by Zacks Equity Research
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.
Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
by Zacks Equity Research
On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.
BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session.
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.
Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.
Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.
Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.
ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.
Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.
Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.
Zoetis (ZTS) Beats Earnings, Revenue Estimates in Q1
by Zacks Equity Research
Zoetis Inc. (ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.
Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.